Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses

NCT ID: NCT00460382

Last Updated: 2010-09-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 103 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-05-31
• Study Completion Date: 2009-09-30

Brief Summary

The purpose of this study is to look at the safety and efficacy of a combination of 3 new antiretroviral drugs: darunavir, etravirine and MK-0518 (raltegravir) in patients who have multi-resistant viruses and limited treatment options. An optimized background regimen that may include nucleoside reverse transcriptase inhibitors (NRTIs) and enfuvirtide can be added, if possible, to this combination. Patients will undergo treatment for 48 weeks and virological efficacy will be evaluated at week 24.

Detailed Description

Methods: A phase II pilot, prospective, open label, single arm multicentric clinical trial assessing a darunavir/ritonavir, etravirine and MK-0518-containing regimen, if possible associated to an optimized background regimen that may include NRTIs and enfuvirtide, in HIV-1 infected patients failing combination antiretroviral therapy with multi-resistant viruses.

Treatment strategy: Patients will receive raltegravir (MK-0518), darunavir/ritonavir (TMC114/r) and etravirine (TMC125) and if possible an optimized background therapy.

• raltegravir (MK-0518) (400 mg x 2/d = one 400 mg pill twice daily)
• darunavir (600 mg x 2/d= two 300 mg pills twice daily with meal)
• ritonavir (100 mg x 2/d = one 100 mg pill twice daily with meal)
• etravirine (200 mg x 2/d = two 100 mg pills twice daily with meal)
• if possible an optimized background therapy: may include NRTI(s) and enfuvirtide but not nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). NRTIs choice is left to the clinician's discretion. Enfuvirtide is highly recommended in enfuvirtide-naive patients but is left to the clinician.

Main outcome: proportion of patients with HIV RNA levels of less than 50 copies/ml in an intent to treat analysis at W24.

Secondary outcomes: proportions of patients with HIV RNA levels of less than 50 copies/ml at week 48, with HIV RNA levels of less than 400 copies/ml at week 24 and 48; HIV RNA level evolution between baseline and week 48; HIV proviral DNA and 2LTR circle HIV DNA between baseline and week 48; number and type of resistance mutations in case of virologic failure occurrence; CD4 lymphocyte count and proportion evolution between baseline and week 48; HIV infection progression; frequency of the study regimen modifications and interruption; study regimen tolerance; study regimen adherence; association between study drugs' minimum concentrations at week 4 and virologic success at week 24; evolution of pharmacokinetic parameters of study drugs between week 1 and week 4 in the Pharmacokinetic substudy.

Sample size: 103 patients

Enrollment period: 24 weeks

Patient's participation duration: 52 weeks

An extended follow-up (from week 52 to week 96) has been added in April 2008.

Conditions

HIV Infections

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

raltegravir potassium

400 mg twice a day

Intervention Type: DRUG

darunavir/ritonavir

2 pills of 300 mg twice a day

Intervention Type: DRUG

etravirine

2 pills of 100 mg twice a day

Intervention Type: DRUG

Optimized background regimen

NRTIs and or enfuvirtide (investigator choice)

Intervention Type: DRUG

Other Intervention Names

Isentress; Prezista; TMC125; OBT; enfuvirtide

Eligibility Criteria

Inclusion Criteria

• Age: 18 years and above
• Documented HIV-1 infection.
• History of virological failure on NNRTIs (patients with a history of toxicity to nevirapine and efavirenz may be enrolled in this study).
• On a combination antiretroviral therapy for at least 8 weeks prior to the screening visit (if on tipranavir, or enfuvirtide these drugs should have been introduced more than 8 weeks before the screening visit).
• Patient naive to darunavir, etravirine and to integrase inhibitors
• Plasma viral load at screening visit over 1000 copies/ml, (no CD4 restriction).
• Genotypic resistance testing at the screening visit:

• Protease inhibitor mutations: over or equal to 3 primary protease inhibitor mutations among: D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, I54M, L76V, V82A/F/L/T/S, I84V, N88S and L90M (IAS list 2006) but below or equal to 3 mutations among the following: V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V et L89V (virus sensitivity to darunavir/ritonavir).
• Reverse transcriptase mutations: over or equal to 3 NRTI mutations (among IAS list) and below or equal to 3 mutations among: A98G, L100I, K101Q/P/E, K103H/N/S/T, V106A/M, V108I, E138G/K/Q, V179D/E/F/G/I, Y181C/I/V/C/H/L, Y188C/H/L, G190A/C/E/Q/S, P225H, F227C/L, M230I/L, P236L, K238N/T and Y318F (virus sensitivity to etravirine)

Exclusion Criteria

• Non effective barrier contraception in women of child bearing potential
• Pregnant women or women who are breastfeeding
• Opportunistic infection at the acute phase
• Decompensated cirrhosis (stage B or C of Child-Pugh score)
• Malignancy requiring chemotherapy or radiotherapy
• Contraindicated medications being taken by the patient (listed in protocol)
• Allergy to the active substances and expedients of darunavir, etravirine and raltegravir.
• Haemoglobin < 7g/dl, neutrophil cell count < 500/mm3, platelets < 50,000/mm3, creatinine clearance < 50 ml/mn, P. alkaline, AST, ALT or total bilirubin over or equal to 3 times normal values.
• Patients receiving experimental agents with an exclusion period for participation in other studies applicable at the screening visit of the current study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: collaborator

Janssen-Cilag Tibotec

UNKNOWN

Sponsor Role: collaborator

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

Sponsor Role: lead

Responsible Party

French National Agency for Research on AIDS and Viral Hepatitis

Principal Investigators

Yazdan YAZDANPANAH, MD PHD

Role: PRINCIPAL_INVESTIGATOR

Hôpital Tourcoing FRANCE

Geneviève CHENE, MD PHD

Role: STUDY_DIRECTOR

INSERM U897 BORDEAUX FRANCE

Locations

Hôpital Gustave Dron, Service Maladies Infectieuses

Tourcoing, , France

Countries

France

Other Identifiers

ANRS 139 TRIO

Identifier Type: -

Identifier Source: secondary_id

2007-000670-23

Identifier Type: -

Identifier Source: org_study_id